|
| 38086008 | CML and the WHO: Why? | J Clin Oncol | 2024 |
| 36266759 | Impact of academic medical center access on outcomes in multiple myeloma. | Am J Hematol | 2023 |
| 34649277 | A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. | Blood Adv | 2022 |
| 35576960 | Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. | Lancet Haematol | 2022 |
| 35876645 | Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. | Br J Haematol | 2022 |
| 35180010 | Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. | J Clin Oncol | 2022 |
| 34482403 | Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. | Blood | 2022 |
| 34781268 | Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 31409922 | In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. | Leukemia | 2020 |
| 32409689 | Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. | Leukemia | 2020 |
| 30563936 | Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. | Clin Cancer Res | 2019 |
| 31756575 | Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. | Leuk Res | 2019 |
| 31869360 | Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia. | PLoS One | 2019 |
| 31648319 | The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. | Blood Adv | 2019 |
| 31325373 | Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant. | Transpl Infect Dis | 2019 |
| 28436250 | Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. | J Oncol Pharm Pract | 2018 |
| 27750463 | Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib. | Leuk Lymphoma | 2017 |
| 28465516 | Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. | Leukemia | 2017 |
| 28852963 | Minimal Residual Disease Eradication in CML: Does It Really Matter? | Curr Hematol Malig Rep | 2017 |
| 24824144 | Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. | Am J Clin Oncol | 2016 |
| 26648538 | Age-related mutations and chronic myelomonocytic leukemia. | Leukemia | 2016 |
| 27729941 | Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. | Ecancermedicalscience | 2016 |
| 27480386 | Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. | Leukemia | 2016 |
| 27277816 | Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. | Cancer Immunol Immunother | 2016 |
| 26781820 | Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. | Clin Genitourin Cancer | 2016 |
| 26752680 | A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. | Leuk Lymphoma | 2016 |
| 25134459 | Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. | Leukemia | 2015 |
| 25688268 | Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. | J Oncol | 2015 |
| 25497584 | Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. | Clin Genitourin Cancer | 2015 |
| 25573989 | shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. | Blood | 2015 |
| 23962746 | Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. | Eur Urol | 2014 |
| 25059215 | Systemic mastocytosis in a patient with Cowden syndrome. | Am J Hematol | 2014 |
| 25023360 | Primary non-Hodgkin lymphoma of the ovary. | Semin Oncol | 2014 |
| 25132497 | BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. | Cancer Cell | 2014 |
| 24787966 | First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. | Clin Genitourin Cancer | 2014 |
| 24707942 | Aggressive systemic mastocytosis mimicking lymphoma: description of an unusual presentation and review of the literature on current management strategies. | Leuk Lymphoma | 2014 |
| 24485801 | A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. | Clin Genitourin Cancer | 2014 |
| 24220220 | Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. | Clin Genitourin Cancer | 2014 |
| 22307799 | An inherited disorder with splenomegaly, cytopenias, and vision loss. | Am J Med Genet A | 2012 |
| 22491044 | Locally recurrent endometrial cancer: a case report. | J Natl Compr Canc Netw | 2012 |